UK markets close in 4 hours 58 minutes

Centessa Pharmaceuticals Limited (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.91-0.02 (-0.22%)
At close: 04:00PM EST
8.80 -0.11 (-1.23%)
After hours: 04:02PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.11B
Enterprise value 1.06B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-59.03%
S&P500 52-week change 322.74%
52-week high 326.90
52-week low 38.58
50-day moving average 311.62
200-day moving average 317.52

Share statistics

Avg vol (3-month) 3195.6k
Avg vol (10-day) 3233.81k
Shares outstanding 589.9M
Implied shares outstanding 6N/A
Float 839.43M
% held by insiders 11.92%
% held by institutions 163.45%
Shares short (30 Dec 2021) 42.21M
Short ratio (30 Dec 2021) 412.51
Short % of float (30 Dec 2021) 4N/A
Short % of shares outstanding (30 Dec 2021) 42.46%
Shares short (prior month 29 Nov 2021) 42.1M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-331.81M
Diluted EPS (ttm)-3.69
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)578.81M
Total cash per share (mrq)6.44
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)20.99
Book value per share (mrq)6.11

Cash flow statement

Operating cash flow (ttm)-72.32M
Levered free cash flow (ttm)N/A